Skip to content
Clinical Trials – home

Institutul National de Diabet, Nutritie si Boli Metabolice "N.C. Paulescu"

Verified siteinfo

Romania Strada Movila Ion 5-7, 020475 Bucharest, Romania

  • 4 trials recruiting
  • Type 2 diabetes mellitus · Arteriosclerosis · Cardiovascular disorder
  • Adult patients

About Specializations

Institutul National de Diabet, Nutritie si Boli Metabolice "N.C. Paulescu" in Bucharest, Romania specialises in clinical trials of conditions such as Type 2 diabetes mellitus, Arteriosclerosis, Cardiovascular disorder, Hypertension, and other specialisations. This site conducts important research.

Main research areas of the site

Diabetes and Metabolic Disease Research

At the Institutul National de Diabet, Nutritie si Boli Metabolice "N.C. Paulescu" in Bucuresti, most studies focus on Nutritional and Metabolic Diseases, especially Type 2 Diabetes and related problems such as poor glycaemic control and excess body weight. The trials are designed to test new treatment options, compare them with established therapies, and improve everyday diabetes management.

  • Evaluating new therapies to improve blood sugar control in people with Type 2 Diabetes Mellitus
  • Comparing treatment approaches for diabetes that is not well controlled with standard care
  • Studying the combined impact of glucose-lowering and weight-related treatments

This work reflects a strong clinical focus on helping patients achieve better long-term metabolic control while also addressing broader health risks linked to diabetes.

Cardiovascular Disease Prevention and Outcomes

Another major area of research at this site is Cardiovascular Diseases, with trials centered on atherosclerotic cardiovascular disease, heart failure, hypertension, and related risk reduction. These studies aim to determine whether newer therapies can lower the chance of serious heart and vascular events in people already at high risk.

  • Testing treatments for ASCVD and primary prevention of cardiovascular events
  • Assessing strategies to reduce the risk of heart failure and cardiovascular death
  • Studying therapies for patients with elevated Lp(a) and other major risk factors

The site’s cardiovascular portfolio emphasizes prevention, long-term outcomes, and improving protection for patients with complex cardiometabolic disease.

Diabetes-Related Complications and Organ Protection

Research here also addresses complications linked to diabetes, including diabetic retinopathy and cardiovascular risk in people with other chronic conditions such as ESKD. These trials are exploring whether treatment can help protect organs beyond glucose lowering alone.

  • Studying eye disease progression in people with Type 2 Diabetes
  • Evaluating inflammation and cardiovascular risk in patients with advanced kidney disease
  • Exploring broader safety and long-term benefit of therapies used in chronic metabolic disease

This mix of studies shows a practical interest in preventing complications and improving quality of life for people living with long-standing metabolic illness.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Strada Movila Ion 5-7020475 BucharestRomania
Recruiting now
4 trials
Conditions studied
6
Partner status
Verified site

More sites in BucharestRomania

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

13 clinical trials

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study on the Effects of Semaglutide on Diabetic Eye Disease in People with Type 2 Diabetes

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Study on the Effects of Maridebart Cafraglutide for Adults with Type 2 Diabetes

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.